Company intelligence / Profile preview
Applied Therapeutics, Inc.
- Ownership
- Public · APLT
- Employees
- ~35
- Development stage
- Other
Overview
Applied Therapeutics has completed Phase 3 trials for govorestat (AT-007) in galactosemia and received a Complete Response Letter from the FDA in November 2024. The company reported positive 12-month interim results from the Phase 3 INSPIRE trial for SORD Deficiency in February 2024, with primary endpoints and several key secondary endpoints achieved. Their AT-001 compound for Diabetic Cardiomyopathy has completed Phase 3 trials.
- Therapeutic areas
- CardiovascularMetabolic DisordersOphthalmologyEndocrinologyRare DiseasesNeurology
- Modalities
- Small molecules (Aldose Reductase Inhibitors)
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Applied Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Applied Therapeutics, Inc..